相似文献
1
How pharmaceuticals are developed.
J Am Dent Assoc. 1994 Jan;125 Suppl:40S-44S. doi: 10.14219/jada.archive.1994.0259.
2
The special treatment.
Nat Biotechnol. 2008 May;26(5):487-9. doi: 10.1038/nbt0508-487.
3
Regulators scramble to tighten loopholes after heparin debacle.
Nat Biotechnol. 2008 May;26(5):477-8. doi: 10.1038/nbt0508-477.
4
Today's FDA.
N Engl J Med. 2005 Jan 20;352(3):293-7. doi: 10.1056/NEJMsb042278.
5
Paying for drug approvals--who's using whom?
N Engl J Med. 2007 Apr 26;356(17):1697-700. doi: 10.1056/NEJMp078041. Epub 2007 Apr 13.
6
What ails the FDA?
N Engl J Med. 2005 Mar 17;352(11):1063-6. doi: 10.1056/NEJMp058003.
7
Two-stage drug approval would reduce the risks.
Nature. 2005 May 12;435(7039):143. doi: 10.1038/435143b.
8
Federal Drug Administration authority and the emergency nurse: implications for patient safety.
J Emerg Nurs. 2006 Oct;32(5):449-50. doi: 10.1016/j.jen.2006.05.028. Epub 2006 Aug 7.
9
FDA embraces risk-management approach.
Nat Biotechnol. 2003 Oct;21(10):1120-1. doi: 10.1038/nbt877.
10
Avoiding the regulatory capture of the Food and Drug Administration.
Arch Intern Med. 2007 Apr 9;167(7):732-3. doi: 10.1001/archinte.167.7.732-b.
Zotero 插件